Long-Term Inhaled Nitric Oxide plus Dipyridamole for Pulmonary Arterial Hypertension

Publisher： Karger

E-ISSN： 1423-0356|72|4|419-422

ISSN： 0025-7931

Source： Respiration, Vol.72, Iss.4, 2005-07, pp. : 419-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients

By Sasayama Shigetake   Satoh Toru   Izumi Tohru   Yoshida Shunji   Kyotani Shingo   Tahara Nobuhiro  

Current Medical Research and Opinion, Vol. 23, Iss. 2, 2007-02 ,pp. : 395-400

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension

By  

Respiration, Vol. 89, Iss. 6, 2015-06 ,pp. : 515-524

Karger

Access to resources Recommend Favorite

Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?

By Clozel Martine  

Annals of Medicine, Vol. 35, Iss. 8, 2003-12 ,pp. : 605-613

Informa Healthcare

Access to resources Recommend Favorite

Intermediate- and long-term follow-up of device closure of patent arterial duct with severe pulmonary hypertension: factors predicting outcome

By  

Cardiology in the Young, Vol. 27, Iss. 1, 2016-05 ,pp. : 26-36

Cambridge University Press

Access to resources Recommend Favorite

Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension—Bridge‐to‐transplant or long‐term treatment?

By  

PEDIATRIC TRANSPLANTATION, Vol. 22, Iss. 2, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite